B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Lung cancer is the leading cause of cancer‐related deaths worldwide. Surgery and chemoradiation are the standard of care in early stages of non‐small cell lung cancer (NSCLC), while immunotherapy is the standard of care in late‐stage NSCLC. The immune composition of the tumor microenvironment (TME) is recognized as an indicator for responsiveness to immunotherapy, although much remains unknown about its role in responsiveness to surgery or chemoradiation. In this pilot study, we characterized the NSCLC TME using mass cytometry (CyTOF) and bulk RNA sequencing (RNA‐Seq) with deconvolution of RNA‐Seq being performed by Kassandra, a recently published deconvolution tool. Stratification of patients based on the intratumoral abundance of B cells identified that the B‐cell rich patient group had increased expression of CXCL13 and greater abundance of PD1+ CD8 T cells. The presence of B cells and PD1+ CD8 T cells correlated positively with the presence of intratumoral tertiary lymphoid structures (TLS). We then assessed the predictive and prognostic utility of these cell types and TLS within publicly available stage 3 and 4 lung adenocarcinoma (LUAD) RNA‐Seq datasets. As previously described by others, pre‐treatment expression of intratumoral 12‐chemokine TLS gene signature is associated with progression free survival (PFS) in patients who receive treatment with immune checkpoint inhibitors (ICI). Notably and unexpectedly pre‐treatment percentages of intratumoral B cells are associated with PFS in patients who receive surgery, chemotherapy, or radiation. Further studies to confirm these findings would allow for more effective patient selection for both ICI and non‐ICI treatments.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas
- Date Crossref
- 16/02/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Massachusetts General Hospital Vaccine and Immunotherapy Center pays non établi dans la noticeÉtablissement de santé
-
Addgene pays non établi dans la noticeOrganisation à but non lucratif
-
Avera Health pays non établi dans la noticeÉtablissement de santé
-
Harvard Medical School Boston Massachusetts USA pays non établi dans la noticeInstitution
-
BostonGene Waltham Massachusetts USA pays non établi dans la noticeOrganisation à but non lucratif
-
Avera Institute of Human Genetics Sioux Falls South Dakota USA pays non établi dans la noticeStructure de recherche
Harvard University, Vaccine and Immunotherapy Center — Massachusetts General Hospital et Addgene, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.